Humacyte (NASDAQ:HUMA) completed enrollment of its Phase 2/3 vascular trauma trial that is expected to support a BLA filing for Humacyte’s human acellular vessel (HAV) in vascular trauma repair planned for the fourth...
Piper Sandler downgraded Humacyte (NASDAQ:HUMA) to “underweight” from “overweight” and reduced its price target to $4 from $10, citing the sizable stock pullback in the sector. The stock closed at $5.37 on May 13. The...